Activation of reactive oxygen species/AMP activated protein kinase signaling mediates fisetin-induced apoptosis in multiple myeloma U266 cells

Cancer Letters

Volumn 319, Issue 2, 2012, Pages 197-202

  Jang, Ki Young ^a   Jeong, Soo Jin ^a   Kim, Sun Hee ^a   Jung, Ji Hoon ^a   Kim, Ji Hyun ^a   Koh, Wonil ^a   Chen, Chang Yan ^b   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AMPK; Apoptosis; Fisetin; Multiple myeloma; ROS

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYLCYSTEINE; BIM PROTEIN; CASPASE 3; FISETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FLAVONOIDS; HUMANS; MULTIPLE MYELOMA; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84862819739     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.008     Document Type: Article

References (36)

1. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3-21.
2. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks, Prescrire Int. 15 (2006) 98-100.
3. Suter M., Riek U., Tuerk R., Schlattner U., Wallimann T., Neumann D. Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J. Biol. Chem. 2006, 281:32207-32216.
4. Hardie D.G., Scott J.W., Pan D.A., Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 2003, 546:113-120.
5. Carling D. The AMP-activated protein kinase cascade - a unifying system for energy control. Trends Biochem. Sci. 2004, 29:18-24.
6. Shackelford D.B., Shaw R.J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9:563-575.
7. Zhang W.B., Wang Z., Shu F., Jin Y.H., Liu H.Y., Wang Q.J., et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J. Biol. Chem. 2010, 285:40461-40471.
8. Kim H.J., Kim S.K., Kim B.S., Lee S.H., Park Y.S., Park B.K., et al. Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J. Agric. Food. Chem. 2010, 58:8643-8650.
9. Kim do Y., Park M.W., Yuan H.D., Lee H.J., Kim S.H., Chung S.H. Compound K induces apoptosis via CAMK-IV/AMPK pathways in HT-29 colon cancer cells. J. Agric. Food. Chem. 2009, 57:10573-10578.
10. de Whalley C.V., Rankin S.M., Hoult J.R., Jessup W., Leake D.S. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages. Biochem. Pharmacol. 1990, 39:1743-1750.
11. Lee J.D., Huh J.E., Jeon G., Yang H.R., Woo H.S., Choi D.Y., et al. Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. Int. Immunopharmacol. 2009, 9:268-276.
12. Ravichandran N., Suresh G., Ramesh B., Siva G.V. Fisetin, a novel flavonol attenuates benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Food Chem. Toxicol. 2011, 49:1141-1147.
13. Sung B., Pandey M.K., Aggarwal B.B. Fisetin, an inhibitor of cyclin-dependent kinase 6, down-regulates nuclear factor-kappaB-regulated cell proliferation, antiapoptotic and metastatic gene products through the suppression of TAK-1 and receptor-interacting protein-regulated IkappaBalpha kinase activation. Mol. Pharmacol. 2007, 71:1703-1714.
14. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., Tatar M., et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430:686-689.
15. Plumb J.A., Milroy R., Kaye S.B. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 1989, 49:4435-4440.
16. Kim S.H., Ahn K.S., Jeong S.J., Kwon T.R., Jung J.H., Yun S.M., et al. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells. Eur. J. Pharmacol. 2011, 654:10-16.
17. Kim J.H., Jeong S.J., Kwon T.R., Yun S.M., Jung J.H., Kim M., et al. Cryptotanshinone enhances TNF-alpha-induced apoptosis in chronic myeloid leukemia KBM-5 cells. Apoptosis 2011, (Epub ahead of print).
18. Hsu Y.C., Meng X., Ou L., Ip M.M. Activation of the AMP-activated protein kinase-p38 MAP kinase pathway mediates apoptosis induced by conjugated linoleic acid in p53-mutant mouse mammary tumor cells. Cell. Signal. 2010, 22:590-599.
19. Gleason C.E., Lu D., Witters L.A., Newgard C.B., Birnbaum M.J. The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J. Biol. Chem. 2007, 282:10341-10351.
20. Egan D., Kim J., Shaw R.J., Guan K.L. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy 2011, 7:643-644.
21. Jing K., Song K.S., Shin S., Kim N., Jeong S., Oh H.R., et al. Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. Autophagy 2011, 7:1348-1358.
22. Kim J., Kundu M., Viollet B., Guan K.L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 2011, 13:132-141.
23. Mann S.S., Hammarback J.A. Molecular characterization of light chain 3. A microtubule binding subunit of MAP1A and MAP1B. J. Biol. Chem. 1994, 269:11492-11497.
24. Chen M.B., Shen W.X., Yang Y., Wu X.Y., Gu J.H., Lu P.H. Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J. Cell. Physiol. 2011, 226:1915-1925.
25. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005, 2:9-19.
26. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2003, 2:28.
27. Canto C., Auwerx J. AMP-activated protein kinase and its downstream transcriptional pathways. Cell. Mol. Life Sci. 2010, 67:3407-3423.
28. Salminen A., Hyttinen J.M., Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. 2011.
29. Viollet B., Andreelli F. AMP-activated protein kinase and metabolic control. Handb. Exp. Pharmacol. 2011, 303-330.
30. Wang W., Guan K.L. AMP-activated protein kinase and cancer. Acta Physiol. (Oxf) 2009, 196:55-63.
31. Yun H., Ha J. AMP-activated protein kinase modulators: a patent review (2006-2010). Expert Opin. Ther. Pat. 2011.
32. Khan N., Afaq F., Khusro F.H., Adhami V.M., Suh Y., Mukhtar H. Dual inhibition of PI3K/AKT and mTOR signaling in human non-small cell lung cancer cells by a dietary flavonoid fisetin. Int. J. Cancer 2011.
33. Suh Y., Afaq F., Khan N., Johnson J.J., Khusro F.H., Mukhtar H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis 2011, 31:1424-1433.
34. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discovery 2009, 8:579-591.
35. Chen G., Zhang X., Zhao M., Wang Y., Cheng X., Wang D., et al. Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. BMC Cancer 2011, 11:170.
36. Kim J.H., Jeong S.J., Kwon T.R., Yun S.M., Jung J.H., Kim M., et al. Cryptotanshinone enhances TNF-alpha-induced apoptosis in chronic myeloid leukemia KBM-5 cells. Apoptosis 2011, 16:696-707.